The traditional approach to drug design has produced few drugs and proves to have a very low or even negative return on investment. Common Pharma has a new approach to drug design that produces safer, lower cost and more effective medications.

The chemotherapeutic agents for both infectious and cancer indications have been very toxic with very low rate of efficacy, high cost and small improvement in life expectancy.